BIO-TECHNE Corp OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax
BIO-TECHNE Corp (TECH) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax of $398.00 thousand for the 12-month period ending 2018-06-30, per its 10-K filed 2020-08-26.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax · last filed 2020-08-26
- BIO-TECHNE Corp oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2018-06-30 was $5.14M.
- BIO-TECHNE Corp oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2018-03-31 was -$10.12M, a 3553.92% decline year-over-year.
- BIO-TECHNE Corp oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2017-12-31 was $799.00K.
- BIO-TECHNE Corp oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2017-09-30 was $4.58K.
- BIO-TECHNE Corp oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2018 was $398.00K.
- BIO-TECHNE Corp oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2017 was -$6.50M, a 271.35% decline from fiscal 2016.
- BIO-TECHNE Corp oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2016 was $3.79M, a 2.59% decline from fiscal 2015.
- BIO-TECHNE Corp oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2015 was $3.90M.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 3 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 9 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 12 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2018-06-30 | $5.14M derived: 10-K 12 month − 10-Q 9 month · filed 2020-08-26 | -$4.98M derived: sum of 2 quarters · filed 2020-08-26 | -$4.18M derived: sum of 3 quarters · filed 2020-08-26 | $398.00K 10-K · filed 2020-08-26 | |||
| 2018-03-31 | -$10.12M 10-Q · filed 2018-05-09 | -$9.32M derived: sum of 2 quarters · filed 2018-05-09 | -$4.75M 10-Q · filed 2018-05-09 | -$14.05M derived: sum of 4 quarters · filed 2019-11-06 | |||
| 2017-12-31 | $799.00K 10-Q · filed 2018-02-08 | $5.38M 10-Q · filed 2018-02-08 | -$3.93M derived: sum of 3 quarters · filed 2019-11-06 | -$3.64M derived: sum of 4 quarters · filed 2019-11-06 | |||
| 2017-09-30 | $4.58K 10-Q · filed 2017-11-09 | -$4.73M derived: sum of 2 quarters · filed 2019-11-06 | -$4.44M derived: sum of 3 quarters · filed 2019-11-06 | -$6.33M derived: sum of 4 quarters · filed 2019-11-06 | |||
| 2017-06-30 | -$4.73M derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-11-06 | -$4.44M derived: sum of 2 quarters · filed 2019-11-06 | -$6.33M derived: sum of 3 quarters · filed 2019-11-06 | -$6.50M 10-K/A · filed 2019-11-06 | |||
| 2017-03-31 | $293.00K 10-Q · filed 2018-05-09 | -$293.00K 10-Q · filed 2017-05-10 | -$1.60M derived: sum of 2 quarters · filed 2018-05-09 | -$1.77M 10-Q · filed 2018-05-09 | $1.77M 10-Q · filed 2017-05-10 | $6.11M derived: sum of 4 quarters · filed 2018-08-27 | |
| 2016-12-31 | -$1.89M 10-Q · filed 2018-02-08 | -$2.06M 10-Q · filed 2018-02-08 | $5.82M derived: sum of 3 quarters · filed 2018-08-27 | $2.21M derived: sum of 4 quarters · filed 2018-08-27 | |||
| 2016-09-30 | -$171.00 10-Q · filed 2017-11-09 | $7.71M derived: sum of 2 quarters · filed 2018-08-27 | $4.10M derived: sum of 3 quarters · filed 2018-08-27 | $633.83K derived: sum of 4 quarters · filed 2018-08-27 | |||
| 2016-06-30 | $7.71M derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-27 | $4.10M derived: sum of 2 quarters · filed 2018-08-27 | $634.00K derived: sum of 3 quarters · filed 2018-08-27 | $3.79M 10-K · filed 2018-08-27 | -$3.79M 10-K · filed 2016-08-29 | ||
| 2016-03-31 | -$3.61M 10-Q · filed 2017-05-10 | -$7.08M derived: sum of 2 quarters · filed 2017-05-10 | -$3.92M 10-Q · filed 2017-05-10 | ||||
| 2015-12-31 | -$3.47M 10-Q · filed 2017-02-09 | $306.00K 10-Q · filed 2017-02-09 | |||||
| 2015-09-30 | $3.75K 10-Q · filed 2016-11-09 | ||||||
| 2015-06-30 | $3.90M 10-K · filed 2016-08-29 | ||||||
| 2014-06-30 | -$17.11M 10-K · filed 2016-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |